These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11392339)

  • 1. Pemoline hepatotoxicity and postmarketing surveillance.
    Safer DJ; Zito JM; Gardner JE
    J Am Acad Child Adolesc Psychiatry; 2001 Jun; 40(6):622-9. PubMed ID: 11392339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A surveillance method for the early identification of idiosyncratic adverse drug reactions.
    Etwel FA; Rieder MJ; Bend JR; Koren G
    Drug Saf; 2008; 31(2):169-80. PubMed ID: 18217792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity due to pemoline. Report of two cases.
    Tolman KG; Freston JW; Berenson MM; Sannella JJ
    Digestion; 1973; 9(6):532-9. PubMed ID: 4787851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemoline hepatotoxicity in children.
    Marotta PJ; Roberts EA
    J Pediatr; 1998 May; 132(5):894-7. PubMed ID: 9602211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four cases of severe hepatotoxicity associated with pemoline: possible autoimmune pathogenesis.
    Rosh JR; Dellert SF; Narkewicz M; Birnbaum A; Whitington G
    Pediatrics; 1998 May; 101(5):921-3. PubMed ID: 9565425
    [No Abstract]   [Full Text] [Related]  

  • 6. Pemoline-associated hepatic failure: a critical analysis of the literature.
    Shevell M; Schreiber R
    Pediatr Neurol; 1997 Jan; 16(1):14-6. PubMed ID: 9044395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data.
    Morrato EH; Staffa JA
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):104-12. PubMed ID: 16821248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemoline therapy resulting in liver transplantation.
    Adcock KG; MacElroy DE; Wolford ET; Farrington EA
    Ann Pharmacother; 1998 Apr; 32(4):422-5. PubMed ID: 9562136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatotoxicity due to pemoline (Cylert): a report of two cases.
    Pratt DS; Dubois RS
    J Pediatr Gastroenterol Nutr; 1990 Feb; 10(2):239-41. PubMed ID: 2303976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemoline in adult attention deficit hyperactivity disorder: predictors of nonresponse.
    Heiligenstein E; Anders J
    J Am Coll Health; 1997 Mar; 45(5):225-9. PubMed ID: 9069682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemoline-associated hepatic injury.
    Nehra A; Mullick F; Ishak KG; Zimmerman HJ
    Gastroenterology; 1990 Nov; 99(5):1517-9. PubMed ID: 2210262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inappropriate pemoline therapy leading to acute liver failure and liver transplantation.
    Abbiati C; Vecchi M; Rossi G; Donata MF; de Franchis R
    Dig Liver Dis; 2002 Jun; 34(6):447-51. PubMed ID: 12132793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of compliance with FDA recommendations for pemoline (Cylert).
    Willy ME; Manda B; Shatin D; Drinkard CR; Graham DJ
    J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):785-90. PubMed ID: 12108802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemoline (Cylert)-induced hepatotoxicity.
    Elitsur Y
    J Pediatr Gastroenterol Nutr; 1990 Jul; 11(1):143-4. PubMed ID: 2388127
    [No Abstract]   [Full Text] [Related]  

  • 15. Pemoline-induced autoimmune hepatitis.
    Sterling MJ; Kane M; Grace ND
    Am J Gastroenterol; 1996 Oct; 91(10):2233-4. PubMed ID: 8855756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder.
    Wilens TE; Biederman J; Spencer TJ; Frazier J; Prince J; Bostic J; Rater M; Soriano J; Hatch M; Sienna M; Millstein RB; Abrantes A
    J Clin Psychopharmacol; 1999 Jun; 19(3):257-64. PubMed ID: 10350032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal and nonfatal hepatotoxicity associated with flutamide.
    Wysowski DK; Freiman JP; Tourtelot JB; Horton ML
    Ann Intern Med; 1993 Jun; 118(11):860-4. PubMed ID: 7683180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemoline-associated fulminant liver failure: testing the evidence for causation.
    Berkovitch M; Pope E; Phillips J; Koren G
    Clin Pharmacol Ther; 1995 Jun; 57(6):696-8. PubMed ID: 7781270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemoline (Cylert): market withdrawal.
    Hogan V
    CMAJ; 2000 Jan; 162(1):106, 110. PubMed ID: 11216184
    [No Abstract]   [Full Text] [Related]  

  • 20. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
    Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
    J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.